| 1. |
|
|
| 2. |
- He, Anna, et al.
(författare)
-
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
- 2020
-
Ingår i: The Lancet. Neurology. - 1474-4465. ; 19:4, s. 307-316
-
Tidskriftsartikel (refereegranskat)abstract
- High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term disability. We therefore aimed to compare long-term disability outcomes between patients who started high-efficacy therapies within 2 years of disease onset with those who started 4-6 years after disease onset.In this retrospective international observational study, we obtained data from the MSBase registry and the Swedish MS registry, which prospectively collect patient data that are specific to multiple sclerosis as part of routine clinical care. We identified adult patients (aged ≥18 years) with relapsing-remitting multiple sclerosis, with at least 6 years of follow-up since disease onset, and who started the high-efficacy therapy (rituximab, ocrelizumab, mitoxantrone, alemtuzumab, or natalizumab) either 0-2 years (early) or 4-6 years (late) after clinical disease onset. We matched patients in the early and late groups using propensity scores calculated on the basis of their baseline clinical and demographic data. The primary outcome was disability, measured with the Expanded Disability Status Score (EDSS; an ordinal scale of 0-10, with higher scores indicating increased disability), at 6-10 years after disease onset, assessed with a linear mixed-effects model.We identified 6149 patients in the MSBase registry who had been given high-efficacy therapy, with data collected between Jan 1, 1975, and April 13, 2017, and 2626 patients in the Swedish MS Registry, with data collected between Dec 10, 1997, and Sept 16, 2019. Of whom, 308 in the MSBase registry and 236 in the Swedish MS registry were eligible for inclusion. 277 (51%) of 544 patients commenced therapy early and 267 (49%) commenced therapy late. For the primary analysis, we matched 213 patients in the early treatment group with 253 in the late treatment group. At baseline, the mean EDSS score was 2·2 (SD 1·2) in the early group and 2·1 (SD 1·2) in the late group. Median follow-up time for matched patients was 7·8 years (IQR 6·7-8·9). In the sixth year after disease onset, the mean EDSS score was 2·2 (SD 1·6) in the early group compared with 2·9 (SD 1·8) in the late group (p<0·0001). This difference persisted throughout each year of follow-up until the tenth year after disease onset (mean EDSS score 2·3 [SD 1·8] vs 3·5 [SD 2·1]; p<0·0001), with a difference between groups of -0·98 (95% CI -1·51 to -0·45; p<0·0001, adjusted for proportion of time on any disease-modifying therapy) across the 6-10 year follow-up period.High-efficacy therapy commenced within 2 years of disease onset is associated with less disability after 6-10 years than when commenced later in the disease course. This finding can inform decisions regarding optimal sequence and timing of multiple sclerosis therapy.National Health and Medical Research Council Australia and MS Society UK.
|
|
| 3. |
- Marzo, T., et al.
(författare)
-
Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells
- 2022
-
Ingår i: Journal of Inorganic Biochemistry. - : Elsevier BV. - 0162-0134. ; 226
-
Tidskriftsartikel (refereegranskat)abstract
- Angiogenin (Ang) is a potent angiogenic protein that is overexpressed in many types of cancer at concentration values correlated to the tumor aggressiveness. Here, by means of an integrated multi-technique approach based on crystallographic, spectrometric and spectroscopic analyses, we demonstrate that the anti-cancer drug oxaliplatin efficiently binds angiogenin. Microscopy cellular studies, carried out on the prostate cancer cell (PC-3) line , show that oxaliplatin inhibits the angiogenin prompting effect on cell proliferation and migration, which are typical features of angiogenesis process. Overall, our findings point to angiogenin as a possible target of oxaliplatin, thus suggesting a potential novel mechanism for the antineoplastic activity of this platinum drug and opening the avenue to novel approaches in the combined anti-cancer anti-angiogenic therapy.
|
|
| 4. |
- Polovodova Asteman, Irina, 1980, et al.
(författare)
-
Spreading of an alien benthic foraminifer in the North Sea: a reason to be worried?
- 2023
-
Ingår i: International Congress FORAMS2023, Perugia, Italy, 25-30th June. - Perugia, Italy : Micropress Europe & The Grzybowski Foundation.
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- In the Skagerrak-Kattegat (eastern North Sea), the alien benthic foraminifer Nonionella sp. T1 (previously referred to as “Nonionella stella”) was reported for the first time in 2011 and 2012 in the Swedish and southern Norwegian fjords, respectively. Based on dated sediment cores its first occurrence can be traced back to the 1980s in the Gullmar Fjord, to the 2000s in the Öresund and to 2010 in the Oslofjord. Since then, Nonionella sp T1 has spread all over the Kattegat and coastal Skagerrak, according to sampling campaigns performed between 2016 and 2022. The species is now highly abundant in the entire Kattegat, including the Öresund, as well as in fjord mouths of the seasonally hypoxic Gullmar Fjord, the oxic Hakefjord and the long-term polluted Idefjord as demonstrated by molecular and morphospecies data. At the same time, Nonionella sp T1 is rare to absent in the Baltic Sea, Skagerrak deep basin and in deep fjords of western and northern Norway. This study shows some preliminary results on the species’ present distribution in the study area and raises questions about the driving factors and potential effects on the local biodiversity.
|
|
